Latest Histone deacetylase Stories
Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Downingtown,
Approximately eight million Americans are afflicted with post-traumatic stress disorder (PTSD). This condition is characterized by severe anxiety that can be traced back to a traumatic event such as a battle or violent attack.
A new study published 26th November in the open access journal PLOS Biology, identifies a new target in the search for therapeutic interventions for Huntington's disease – a devastating late-onset neurodegenerative disorder.
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities.
Drugs that inhibit the activity of enzymes called histone deacetylases (HDACs) are being widely developed for treating cancer and other diseases, with two already on the market.
Exciting new data presented today at the International Liver Congress™ 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.
The commonly-used epilepsy drug, valproic acid (VPA), can have a highly beneficial effect on some babies born with spinal muscular atrophy (SMA), the number one genetic killer during early infancy.
The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research.
A cellular protein called HDAC6, newly characterized as a gatekeeper of steroid biology in the brain, may provide a novel target for treating and preventing stress-linked disorders, such as depression and post-traumatic stress disorder (PTSD), according to research from the Perelman School of Medicine at the University of Pennsylvania.